AB
Elite in Progressive Supranuclear Palsy

Dr. Adam L. Boxer

Memory And Aging Center
San Francisco, CA
Elite
 in Progressive Supranuclear Palsy
Specialties:Neurology
Experience:25 Years
Clinical Trials:Currently Recruiting for 6 Trials
Accepts:Medicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Adam L. Boxer's experience treating your condition:
About Dr. Adam L. Boxer

Adam Boxer is a Neurologist in San Francisco, California. Boxer has been practicing medicine for over 25 years and is rated as an Elite expert by MediFind in the treatment of Progressive Supranuclear Palsy. He is also highly rated in 22 other conditions, according to our data. His top areas of expertise are Progressive Supranuclear Palsy Atypical, Progressive Supranuclear Palsy, Supranuclear Ophthalmoplegia, and Frontotemporal Dementia. He is licensed to treat patients in California.

His clinical research consists of co-authoring 246 peer reviewed articles and participating in 29 clinical trials in the past 15 years. In particular, he has co-authored 78 articles and participated in 15 clinical trials in the study of Progressive Supranuclear Palsy.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Adam L. Boxer it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
1651 4th St, Suite 212, San Francisco, CA 94158
Other Locations
400 Parnassus Ave, San Francisco, CA 94143
Background & Education
Graduate Institution
New York University School Of Medicine, 1998
Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Hospital Affiliations
UCSF Helen Diller Medical Center At Parnassus Heights
San Francisco Medical Center
UCSF Medical Center At Mount Zion
Chinese Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials
Remote Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)
Enrollment Status: Recruiting
Publish Date: November 18, 2022
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Recruiting
Publish Date: November 01, 2022
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enrollment Status: Recruiting
Publish Date: July 08, 2022
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Enrollment Status: Recruiting
Publish Date: May 12, 2022
A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
Enrollment Status: Recruiting
Publish Date: August 02, 2021
Intervention Type: Drug
Study Drug: Syntocinon
Study Phase: Phase 2
The Four-Repeat Tauopathy Neuroimaging Initiative
Enrollment Status: Recruiting
Publish Date: May 20, 2021
Intervention Type: Other
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Active, not recruiting
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
Enrollment Status: Completed
Publish Date: May 21, 2021
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: April 01, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease
Enrollment Status: Active, not recruiting
Publish Date: April 01, 2021
Intervention Type: Drug
Study Drug: Salsalate
Study Phase: Phase 1
A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
Enrollment Status: Completed
Publish Date: November 17, 2020
Intervention Type: Drug
Study Phase: Phase 4
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Biological
Study Phase: Phase 1
Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration
Enrollment Status: Unknown status
Publish Date: August 11, 2020
Intervention Type: Other
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
Enrollment Status: Terminated
Publish Date: May 18, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: April 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 14, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes
Enrollment Status: Terminated
Publish Date: December 19, 2019
Intervention Type: Other, Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: September 04, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: July 26, 2017
Intervention Type: Drug
Study Phase: Phase 1
An Open Label Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations
Enrollment Status: Completed
Publish Date: May 16, 2016
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: January 17, 2013
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 19 Less Clinical Trials -
244 Total Publications
Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers.
Journal: JAMA neurology
Published: November 14, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
WS
Dr. William W. Seeley
Neurology
Elite
Highly rated in
25
conditions
Neurology

University of California San Francisco Health System

Memory And Aging Center

1500 Owens St, 
San Francisco, CA 
 0.3 mi

William Seeley is a Neurologist in San Francisco, California. Seeley has been practicing medicine for over 24 years and is rated as an Elite expert by MediFind in the treatment of Progressive Supranuclear Palsy. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Frontotemporal Dementia, Dementia, Primary Progressive Aphasia, and Progressive Supranuclear Palsy Atypical. He is licensed to treat patients in California.

GR
Dr. Gil D. Rabinovici
Neurology
Elite
Highly rated in
19
conditions
Neurology

University of California San Francisco Health System

Memory And Aging Center

1500 Owens St, 
San Francisco, CA 
 0.3 mi

Gil Rabinovici is a Neurologist in San Francisco, California. Rabinovici has been practicing medicine for over 22 years and is rated as an Elite expert by MediFind in the treatment of Progressive Supranuclear Palsy. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Alzheimer's Disease, Dementia, Primary Progressive Aphasia, and Frontotemporal Dementia. He is licensed to treat patients in California. Rabinovici is currently accepting new patients.

SS
Dr. Salvatore Spina
Neurology
Distinguished
Highly rated in
16
conditions
Neurology

University of California San Francisco Health System

Memory And Aging Center

1500 Owens St, 
San Francisco, CA 
 0.3 mi

Salvatore Spina is a Neurologist in San Francisco, California. Spina has been practicing medicine for over 24 years and is rated as a Distinguished expert by MediFind in the treatment of Progressive Supranuclear Palsy. He is also highly rated in 16 other conditions, according to our data. His top areas of expertise are Corticobasal Degeneration, Frontotemporal Dementia, Dementia, and Alzheimer's Disease. He is licensed to treat patients in California. Spina is currently accepting new patients.